Brind.
  1. Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.

Harvard Bioscience is facing revenue decline due to macro uncertainty over tariffs and ongoing issues regarding NIH funding.

1 report, 1 independent Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Harvard Bioscience is facing revenue decline due to macro uncertainty over tariffs and ongoing issues regarding NIH funding.

Who's involved

What this event is mainly about
Harvard BioscienceChinaNational Institute of Health

How it developed

Newest first. Tap a step to see who reported it.
  1. John Duke is the President and CEO of Harvard Bioscience, which is currently managing sales weighted toward lower-margin products in China.Sub-event
  2. Company revenue decline linked to China market uncertainty and NIH funding issues.1 source

Keep exploring

Part of

Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.

Also in this story

All 6 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GuruFocus.comHarvard Bioscience Inc (HBIO) Q2 2025 Earnings Call Highlights: Navigating Revenue Challenges ... Revenue: $20.5 million, below $23.1 million in the prior year but ahead of guidance of $18 million to